BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget 2016;7:65185-95. [PMID: 27533086 DOI: 10.18632/oncotarget.11218] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Lee M, Abu Rous F, Borczuk A, Liu S, Gadgeel S, Halmos B. Targeting Oncogenic Driver Mutations in Lung Cancer. 2023. [DOI: 10.1017/9781009336123] [Reference Citation Analysis]
2 Li D, Jiang H, Jin F, Pan L, Xie Y, Zhang L, Li C. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients. Genes Genomics 2023;45:93-102. [PMID: 36445572 DOI: 10.1007/s13258-022-01326-w] [Reference Citation Analysis]
3 Li W, Yao H, Gu C, Ren Y, Liu J, An B, Hu W, Li X, Chan AS. Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. Bioorganic Chemistry 2022;129:106188. [DOI: 10.1016/j.bioorg.2022.106188] [Reference Citation Analysis]
4 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
5 Wang T, Wei L, Lu Q, Shao Y, You S, Yin JC, Wang S, Shao Y, Chen Z, Wang Z. Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling. npj Precis Onc 2022;6:84. [DOI: 10.1038/s41698-022-00325-0] [Reference Citation Analysis]
6 Noronha V, Chougule A, Chandrani P, Kaushal RK, Patil VM, Menon N, Kapoor A, Chopade S, Singh A, Shetty O, Dutt A, Banavali S, Prabhash K. Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study. Acta Oncol 2022;:1-5. [PMID: 35972844 DOI: 10.1080/0284186X.2022.2109426] [Reference Citation Analysis]
7 Zhang L, Zheng L, Yang Q, Sun J. The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer. Front Oncol 2022;12:882940. [DOI: 10.3389/fonc.2022.882940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ma Y, Zhao J, Du Y, Wang R, Ji X, Wu J, Guo X, Liu Y, Zhang Y. Multigene Combined Detection by RT-qPCR Using Cytological Specimens. Acta Cytol 2021;65:393-402. [PMID: 34343999 DOI: 10.1159/000514821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Zhang R, Dong L, Yu J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front Oncol 2020;10:544579. [PMID: 33520689 DOI: 10.3389/fonc.2020.544579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol 2020;10:610923. [PMID: 33363040 DOI: 10.3389/fonc.2020.610923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
11 Ma Y, Du Y, Wang R, Ji X, Wu J, Liu Y, Guo X, Zhang Y. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens. Pathol Res Pract 2020;216:153036. [PMID: 32703499 DOI: 10.1016/j.prp.2020.153036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Target Oncol 2019;14:169-78. [PMID: 30888598 DOI: 10.1007/s11523-019-00628-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
13 Tang Z, Wang L, Tang G, Medeiros LJ. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. Int J Mol Sci 2019;20:E3939. [PMID: 31412611 DOI: 10.3390/ijms20163939] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
14 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 16.3] [Reference Citation Analysis]
15 Fan J, Dai X, Wang Z, Huang B, Shi H, Luo D, Zhang J, Cai W, Nie X, Hirsch FR. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions. Clin Lung Cancer 2019;20:e517-30. [PMID: 31138506 DOI: 10.1016/j.cllc.2019.04.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
16 Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med 2019;8:2858-66. [PMID: 31016879 DOI: 10.1002/cam4.2183] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
17 Wang X, Zhong D. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:686-91. [PMID: 30201068 DOI: 10.3779/j.issn.1009-3419.2018.09.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Zeng L, Li Y, Xiao L, Xiong Y, Liu L, Jiang W, Heng J, Qu J, Yang N, Zhang Y. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. Onco Targets Ther 2018;11:6937-45. [PMID: 30410351 DOI: 10.2147/OTT.S176273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
19 Li TT, Gao X, Gao L, Gan BL, Xie ZC, Zeng JJ, Chen G. Role of upregulated miR-136-5p in lung adenocarcinoma: A study of 1242 samples utilizing bioinformatics analysis. Pathol Res Pract 2018;214:750-66. [PMID: 29526559 DOI: 10.1016/j.prp.2018.02.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
20 Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Mod Pathol 2018;31:307-12. [DOI: 10.1038/modpathol.2017.109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
21 Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clin Lung Cancer 2018;19:35-41. [PMID: 28757336 DOI: 10.1016/j.cllc.2017.06.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
22 Zhou Q, Song Y, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Zhang PH, Wu YL. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer 2017;17:462. [PMID: 28673332 DOI: 10.1186/s12885-017-3451-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]